What Merck's Quarter ended Sep 30, 2026 10-Q says: 4 signals
Merck filed its latest 10-Q with the SEC on Nov 4, 2026. It discusses acquisition completed, automation investment and compliance burden.
Get Merck's live signals in Claude or ChatGPT, or by API
What changed at Merck this week? Use Autobound signals for merck.com.- Filed
- Nov 4, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 15
Source: Autobound Signal API · 95 signals tracked for Merck · updated
10-Q · latest 10
What Merck's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 4 signals
Merck closed $647 million acquisition of TARGAN in July 2026
In July 2026, Merck acquired TARGAN, a company developing biodevice solutions for poultry, for $647 million.
$647M
acquisition of TARGAN
vision technologyhigh-speed precision ocular spray technology
Preliminary Injunctions Prohibit Keytruda SC Sales Across Multiple European Countries
Preliminary injunctions have been awarded against Merck, prohibiting continued sales of Keytruda SC in Denmark and Italy and preventing product launches in Germany, The Netherlands, Belgium, Ireland, and France following litigation with Halozyme, Inc.
German GKV-BStabG Health Care Reform Act to Lower Keytruda Revenues
In July 2026, the German parliament approved the GKV-BStabG health care reform law introducing cost-containment measures taking effect on January 1, 2027 that will exert significant downward pressure on revenues, especially for Keytruda.
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 6 signals
Merck faces mandatory drug price setting and signed MFN and GENEROUS agreements with CMS
Under the Inflation Reduction Act, government set prices took effect for Januvia on January 1, 2026, with Janumet scheduled for 2027 and Lenvima for 2028.
Merck acquired TARGAN, Terns Pharmaceuticals, and Cidara Therapeutics in 2026
Merck acquired TARGAN for approximately $650 million in July 2026, Terns Pharmaceuticals for $6.8 billion in May 2026, and Cidara Therapeutics for $9.2 billion in January 2026.
$6.8B
acquisition of Terns Pharmaceuticals, Inc.
vision technologyhigh-speed precision ocular spray technology
In July 2026, Merck acquired privately held biodevice company TARGAN for approximately $650 million to integrate WingScan automated vision technology for poultry gender identification and high-speed precision ocular spray delivery.
$650M
acquisition of TARGAN
vision technologyautomated solutionhigh-speed precision ocular spray technology
On March 16, 2026, a federal district court in Massachusetts issued a preliminary injunction staying the CDC's January 2026 child and adolescent immunization schedule changes.
Merck Suspended China Shipments Due to Elevated Channel Inventory and Lower Gardasil Demand
Merck disclosed that it suspended shipments of Gardasil and Gardasil 9 to China in February 2025 due to lower demand and elevated channel inventory levels.
Merck signed GENEROUS Model agreement with CMS in June 2026
In June 2026, Merck signed an agreement with CMS to participate in the GENEROUS Model, aligning certain medication pricing for participating state Medicaid agencies to international prices.
- SEC EDGAR
10-Q · Quarter ended Mar 31, 2026
Filed · 5 signals
Inflation Reduction Act price setting implemented for Januvia in 2026, Janumet in 2027
Under the Inflation Reduction Act's Drug Price Negotiation Program, the U.S.
Showing 10 of 15 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Merck earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Generic competition and LOEs driving over $2B in headwindsMerck anticipates over $2 billion in revenue headwinds in 2027 stemming from loss of exclusivity (LOE) and generic erosion across mature franchises. This includes generic entrants against BRIDION, Januvia, and Adempas, alongside moderating growth for KEYTRUDA. Sales teams can target units affected by patent expirations as the company seeks operational offsets. | |
| Moderna collaboration advances phase 3 mRNA cancer vaccine trialsMerck presented positive Phase 3 results for entismodigene, an individualized neoantigen mRNA cancer vaccine developed with Moderna, in combination with KEYTRUDA. The companies are currently engaged with the FDA on regulatory submissions and advancing multiple Phase 2 and Phase 3 INTerpath trials across oncology indications. | |
| Dutch court injunction temporarily halts subcutaneous KEYTRUDA rolloutA Dutch court issued an injunction temporarily restricting Merck from supplying subcutaneous pembrolizumab (KEYTRUDA QLEX) in several European markets due to patent litigation surrounding the hyaluronidase component. While the US and core high-adoption markets remain unaffected, commercialization is suspended in Italy, Denmark, Netherlands, France, Belgium, and Ireland pending appeal. | |
| Capital allocation strategy maintains $3B annual share repurchase planMerck reiterated its capital allocation strategy, which includes maintaining a strong investment-grade credit profile, continuing dividend growth, and executing $3 billion in share repurchases for 2026. Management signaled ongoing financial capacity to fund science-driven business development transactions. | |
| Market-wide vaccine hesitancy and utilization declines impact portfolioMerck reported a 13% decline in US CAPVAXIVE sales due to lower adult pneumococcal vaccination rates, which offset market share gains. Management noted that broader market vaccine hesitancy and reduced utilization are key operational headwinds being monitored heading into 2027. | |
| Ongoing multiyear optimization effort partially offsets operating cost increasesMerck cited ongoing multiyear optimization initiatives that helped mitigate operational expense growth in Q3. Operating expenses expanded 12% to $7.4B, with management continuing to focus on structural efficiencies while ramping R&D pipeline and commercial launch spend. |
Signal API · MCP
Track Merck with the Signal API
One POST /v1/companies/enrich call with merck.com returns Merck 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"merck.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Merck 10-Q
When did Merck file its latest 10-Q?
What did Merck disclose in its latest 10-Q?
What did Merck say on its recent earnings calls?
Where can I read Merck's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .